Federal Bureau of Narcotics

The Federal Bureau of Narcotics (FBN), the predecessor to the Drug Enforcement Administration, appears in the book as an institutional opponent of using methadone to treat opioid addiction. Its resistance helped define an enduring boundary between drugs regarded as legitimate medicine and drugs regarded as illicit or dangerous, a boundary that later reappears in disputes over medication-assisted treatment.

Identity and Historical Setting

Methadone was a synthetic painkiller developed for battlefield injuries and recovered from German laboratories shortly after World War II. American researchers learned that it could quell opioid withdrawal. The FBN, however, opposed using one drug to treat addiction to another. The book gives no account of the agency’s internal structure or individual officials; its significance here lies in the position it took and the pressure that position placed on clinicians.

Opposition to Methadone Treatment

The FBN characterized methadone as unsafe after studies found that people addicted to Morphine liked it. The narrative emphasizes the implication beneath that judgment: a medication’s capacity to be pleasurable was treated as evidence against its therapeutic use. In the 1960s, the agency harassed the small number of doctors who used methadone to treat Morphine and Heroin addiction. The conflict therefore extended beyond arguments about a drug’s risks to whether addiction could be treated with medication at all.

Consequences for Treatment Development

Over the following decade, criticism of methadone encouraged researchers to develop compounds intended to block opioid euphoria and dangerous respiratory depression, including effects associated with methadone itself. This research led to Buprenorphine and naltrexone, later marketed as Vivitrol. The account distinguishes this scientific response from the FBN’s opposition: it was researchers’ effort to address the objections and risks associated with maintenance medication, not evidence that the agency endorsed it.

Historical Legacy

The book connects the FBN’s earlier resistance to continuing controversy over medication-assisted treatment. In the Appalachian Bible Belt communities where the painkiller epidemic took root, attitudes toward Suboxone among public-health experts and criminal-justice officials barely overlapped. Although Narcotics Anonymous officially accepted medication-assisted treatment, some longtime members declined to sponsor Tess Henry because she was taking Buprenorphine. That later stigma is not presented as a direct consequence of the FBN’s actions; rather, it echoes the older dispute over whether medication can count as recovery. The FBN’s history thus supplies institutional context for a conflict that persisted long after the agency itself had become the predecessor of the Drug Enforcement Administration.